HealthEquity (NASDAQ:HQY) Given New $115.00 Price Target at BTIG Research

HealthEquity (NASDAQ:HQY) had its target price upped by stock analysts at BTIG Research from $110.00 to $115.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price objective suggests a potential upside of 21.91% from the company’s previous close.

Other research analysts have also issued research reports about the company. Wells Fargo & Company set a $111.00 target price on HealthEquity in a research report on Monday, June 1st. Wall Street Zen lowered HealthEquity from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. BMO Capital Markets upgraded HealthEquity from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $85.00 to $105.00 in a research note on Thursday, April 9th. KeyCorp reaffirmed an “overweight” rating on shares of HealthEquity in a report on Tuesday, May 26th. Finally, Weiss Ratings raised shares of HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, June 5th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $110.93.

HealthEquity Stock Performance

Shares of HQY stock opened at $94.33 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 3.44 and a current ratio of 3.44. HealthEquity has a one year low of $72.76 and a one year high of $105.96. The company’s 50-day simple moving average is $89.96 and its 200-day simple moving average is $84.87. The stock has a market capitalization of $7.89 billion, a price-to-earnings ratio of 35.33, a PEG ratio of 1.61 and a beta of 0.21.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Thursday, May 28th. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.13. HealthEquity had a return on equity of 14.75% and a net margin of 17.25%.The business had revenue of $354.64 million during the quarter, compared to the consensus estimate of $352.02 million. HealthEquity’s revenue for the quarter was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. Equities analysts anticipate that HealthEquity will post 3.92 earnings per share for the current fiscal year.

Insider Transactions at HealthEquity

In other HealthEquity news, EVP Michael Henry Fiore sold 3,142 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $95.00, for a total transaction of $298,490.00. Following the completion of the transaction, the executive vice president directly owned 59,113 shares of the company’s stock, valued at $5,615,735. The trade was a 5.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gayle Furgurson Wellborn sold 2,439 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $90.00, for a total transaction of $219,510.00. Following the completion of the transaction, the director owned 19,733 shares of the company’s stock, valued at approximately $1,775,970. This trade represents a 11.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 17,905 shares of company stock worth $1,651,280. Insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On HealthEquity

Several hedge funds and other institutional investors have recently made changes to their positions in HQY. Acumen Wealth Advisors LLC bought a new stake in HealthEquity during the 4th quarter valued at $27,000. Caitong International Asset Management Co. Ltd grew its stake in shares of HealthEquity by 1,723.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $28,000 after purchasing an additional 293 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of HealthEquity in the fourth quarter worth $28,000. Leonteq Securities AG increased its holdings in shares of HealthEquity by 159.9% during the first quarter. Leonteq Securities AG now owns 382 shares of the company’s stock valued at $32,000 after purchasing an additional 235 shares during the period. Finally, Axiom Investment Management LLC acquired a new position in shares of HealthEquity during the first quarter valued at $33,000. 99.55% of the stock is currently owned by institutional investors and hedge funds.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.